top of page
Market Opportunity
Unmet need for more choice
​
While there is an established market for mitral valve repair, there is still a need for more choice of minimally invasive tools to treat mitral valve regurgitation, especially those that would preserve future treatment options. Preserving future treatment options with a frontline repair technology like CathHELIX is smart for lifetime management of this disease.
™
CathHELIX is an improved first-line technology that is less invasive than surgery and because it preserves future treatment options, patients can be treated earlier.
4 million patients
lack treatment
1
$1.5 billion market today
$5 billion market opportunity
by 2032 for the right technology
2
-
Bank of America Merrill Lynch. The Mitral Valve Market. 10 December 2018.
-
Edwards Lifesciences Investor Meeting, Truist Securities EW report, Industry Estimate
bottom of page